Arthur Kirsch Biography and Net Worth

Director of Liquidia

Mr. Kirsch is Director and Senior Advisor, as well as global head of medical devices and diagnostics, of GCA Global, LLC, a global investment banking firm. Mr. Kirsch has been focused on both M&A and Capital Markets transactions within the healthcare industry for the past 20 years. Mr. Kirsch’s experience spans advising both public and private companies with extensive knowledge of cross border transactions between the U.S. and Asia. Prior to joining GCA Global, he was a executive vice president, head of research at Vector Securities. Previously, Mr. Kirsch was president of Natwest Securities Limited, a foreign owned investment bank. Mr. Kirsch began his career on Wall Street at Drexel Burnham Lambert and eventually became head of the Equity Division and a member of the firm’s Executive Committee. He serves as Chairman of the Board of Directors at Aralez, Inc. a public biopharmaceutical company where he is also Chairman of the Audit Committee. Mr. Kirsch earned a B.S. in Finance at the University of Rhode Island and an MBA from The City University of New York.

What is Arthur S. Kirsch's net worth?: The estimated net worth of Arthur S. Kirsch is at least $1.07 million as of June 1st, 2026. Mr. Kirsch owns 15,000 shares of Liquidia stock worth more than $1,066,050 as of June 19th. This net worth approximation does not reflect any other investments that Mr. Kirsch may own. Learn More about Arthur S. Kirsch's net worth.
How do I contact Arthur S. Kirsch?: The corporate mailing address for Mr. Kirsch and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at [email protected]. Learn More on Arthur S. Kirsch's contact information.
Has Arthur S. Kirsch been buying or selling shares of Liquidia?: Within the last three months, Arthur S. Kirsch has sold $1,731,300.00 in shares of Liquidia stock. Most recently, Arthur S. Kirsch sold 10,000 shares of the business's stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $54.80, for a transaction totalling $548,000.00. Learn More on Arthur S. Kirsch's trading history.
Who are Liquidia's active insiders?: Liquidia's insider roster includes Jason Adair (Chief Business Officer), Stephen Bloch (Director), Dana Boyle (CAO), Roger Jeffs (CEO), Michael Kaseta (CFO), Sanjeev Khindri (Chief Development Officer), Arthur Kirsch (Director), Sarah Krepp (Insider), Paul Manning (Director), Scott Moomaw (Chief Commercial Officer), Rajeev Saggar (Insider), Russell Schundler (General Counsel), and Raman Singh (Director). Learn More on Liquidia's active insiders.
Are insiders buying or selling shares of Liquidia?: In the last year, Liquidia insiders bought shares 1 times. They purchased a total of 5,300 shares worth more than $317,894.00. In the last year, insiders at the sold shares 97 times. They sold a total of 3,546,169 shares worth more than $164,499,745.94. The most recent insider tranaction occured on June, 15th when Director Stephen M Bloch sold 85,062 shares worth more than $6,076,829.28. Insiders at Liquidia own 25.6% of the company. Learn More about insider trades at Liquidia.
Information on this page was last updated on 6/15/2026.

Arthur S. Kirsch Insider Trading History at Liquidia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/3/2026	Sell	10,000	$54.80	$548,000.00
6/2/2026	Sell	5,000	$56.00	$280,000.00	10,000
6/1/2026	Sell	15,000	$60.22	$903,300.00	15,000
11/10/2021	Buy	30,000	$4.24	$127,200.00
11/14/2018	Buy	1,000	$18.45	$18,450.00
11/8/2018	Buy	1,000	$18.25	$18,250.00

Arthur S. Kirsch Buying and Selling Activity at Liquidia

Liquidia Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Today's Range

Now: $71.07

$66.83

$71.99

50 Day Range

MA: $53.10

$36.25

$71.80

2 Week Range

Now: $71.07

$11.85

$73.22

Volume

12,433,656 shs

Average Volume

1,819,188 shs

Market Capitalization

$6.32 billion

P/E Ratio

507.68

Dividend Yield

N/A

Beta

0.58